Steven Cohen’s FibroBiologics FBLG Stock Holding History

Steven Cohen’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-724	Closed	-$3.26K	–	4630
2025 Q4	$3.26K	Buy	+724	New	+$5.1K	﹤0.01%	3856

Other funds holding FBLG

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Steven Cohen's FBLG Position: Q1 2026 in Review

Steven Cohen sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 724 shares — an estimated $3.26K sold.

Steven Cohen first reported a position in FBLG in Q4 2025 and held it in 1 quarter. The position peaked at $3.26K in Q4 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

Steven Cohen reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 724 FibroBiologics shares in Q1 2026, an estimated $3.26K.
Steven Cohen first reported a position in FibroBiologics in Q4 2025 and held it in 1 quarter.
Steven Cohen's FibroBiologics position peaked at $3.26K in Q4 2025.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.